PURPOSE OF REVIEW: Current trends in the management of Behçet's syndrome will be 
reviewed in this article.
RECENT FINDINGS: Biologic agents have gained increasing importance over the 
years in the management of Behçet's syndrome. Long-term results of observational 
studies have shown that anti-tumor necrosis factor agents may be effective in 
Behçet's syndrome patients with refractory eye involvement. Case series 
reporting about use of anti-tumor necrosis factor agents in vascular and 
gastrointestinal involvement have also shown good results. Caution is required 
for infectious complications with these agents. Apremilast is an 
immunomodulatory agent that works through phosphodiesterase 4 inhibition. A 
randomized controlled trial has shown that it is effective for the management of 
oral and genital ulcers and is generally well tolerated.
SUMMARY: The outcome of Behçet's syndrome with major organ involvement has 
improved with more effective management strategies, especially with the use of 
biologic agents in severe cases. Controlled trials are needed to guide 
physicians in making treatment decisions.